Cardinal Health 10-Q 2023-12-31
CAH · CIK 721371 · Form 10-Q · Period ended December 31, 2023 · Filed February 1, 2024
Revenue rose 11.6% to $57.4 billion. Operating margin was 0.8%, against -0.2% a year earlier. Net income was $353 million.
8 sections, 211K characters. Original on sec.gov · ·
| Measure | Quarter ended Dec 31, 2023 | Quarter ended Dec 31, 2022 | Change |
|---|---|---|---|
| Revenue | $57.4B | $51.5B | +11.6% |
| Operating income | $482M | -$119M | n/a |
| Net income | $353M | -$130M | n/a |
| Cash and equivalents | $4.59B | n/a | n/a |
| Operating margin* | 0.8% | -0.2% | +1.1 pts |
From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.
Cover and table of contents
| Table of Contents |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
| ☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended December 31, 2023
or
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ________ to ________
Commission File Number: 1-11373
Cardinal Health, Inc.
(Exact name of registrant as specified in its charter)
| Ohio | 31-0958666 | |||||||||||||||||||
| (State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) | |||||||||||||||||||
| 7000 Cardinal Place | , | Dublin | , | Ohio | 43017 | |||||||||||||||
| (Address of principal executive offices) | (Zip Code) |
(614) 757-5000
(Registrant’s telephone number, including area code)
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Common shares (without par value) | CAH | New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☑ | Accelerated filer | ☐ | ||||||||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ | ||||||||||||||
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ
The number of the registrant’s common shares, without par value, outstanding as of January 26, 2024, was the following:243,233,153.
| Cardinal Health Q2 Fiscal 2024 Form 10-Q |
Table of Contents
About Cardinal Health
Cardinal Health, Inc., an Ohio corporation formed in 1979, is a global healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. We manage our business and report our financial results in two segments: Pharmaceutical and Medical. As used in this report, “we,” “our,” “us,” and similar pronouns refer to Cardinal Health, Inc. and its majority-owned and consolidated subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2024 and fiscal 2023 and to FY24 and FY23 are to the fiscal years ending or ended June 30, 2024 and June 30, 2023, respectively.
Forward-Looking Statements
This Quarterly Report on Form 10-Q for the quarter ended December 31, 2023 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (our “2023 Form 10-K”). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.
Non-GAAP Financial Measures
In the "Overview of Consolidated Results" section of MD&A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the United States Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the “Explanation and Reconciliation of Non-GAAP Financial Measures” section following MD&A in this Form 10-Q.
| 1 | Cardinal Health | Q2 Fiscal 2024 Form 10-Q |
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
| MD&A | Overview |
Management's Discussion and Analysis of Financial Condition and Results of Operations
The discussion and analysis presented below is concerned with material changes in financial condition and results of operations, including amounts and certainty of cash flows from operations and from outside sources, between the periods specified in our condensed consolidated balance sheets at December 31, 2023 and June 30, 2023, and in our condensed consolidated statements of earnings/(loss) for the three and six months ended December 31, 2023 and 2022. All comparisons presented are with respect to the prior-year period, unless stated otherwise. This discussion and analysis should be read in conjunction with the MD&A included in our 2023 Form 10-K.
| 2 | Cardinal Health | Q2 Fiscal 2024 Form 10-Q |
| MD&A | Overview |
Overview of Consolidated Results
Revenue
During the three and six months ended December 31, 2023, revenue increased 12 percent and 11 percent to $57.4 billion and $112.2 billion, respectively, primarily due to branded and specialty pharmaceutical sales growth from existing customers.
GAAP and Non-GAAP Operating Earnings/(Loss)
| Three Months Ended December 31, | Six Months Ended December 31, | ||||||||||||||||||||||||||||||||||
| (in millions) | 2023 | 2022 | Change | 2023 | 2022 | Change | |||||||||||||||||||||||||||||
| GAAP operating earnings/(loss) | $ | 482 | $ | (119) | N.M. | $ | 468 | $ | 18 | N.M. | |||||||||||||||||||||||||
| Surgical gown recall income | (1) | — | (1) | — | |||||||||||||||||||||||||||||||
| State opioid assessment related to prior fiscal years | — | (6) | — | (6) | |||||||||||||||||||||||||||||||
| Shareholder cooperation agreement costs | — | 2 | — | 8 | |||||||||||||||||||||||||||||||
| Restructuring and employee severance | 28 | 17 | 53 | 46 | |||||||||||||||||||||||||||||||
| Amortization and other acquisition-related costs | 63 | 71 | 127 | 142 | |||||||||||||||||||||||||||||||
| Impairments and (gain)/loss on disposal of assets, net | 1 | 710 | 538 | 863 | |||||||||||||||||||||||||||||||
| Litigation (recoveries)/charges, net | (11) | (207) | (52) | (180) | |||||||||||||||||||||||||||||||
| Non-GAAP operating earnings | $ | 562 | $ | 467 | 20 | % | $ | 1,133 | $ | 891 | 27 | % |
The sum of the components and certain computations may reflect rounding adjustments.
We had GAAP operating earnings of $482 million during the three months ended December 31, 2023 and a GAAP operating loss of $119 million during the three months ended December 31, 2022, which reflects the $709 million pre-tax goodwill impairment charge related to the Medical segment recognized during the three months ended December 31, 2022.
We had GAAP operating earnings of $468 million and $18 million during the six months ended December 31, 2023 and 2022, respectively, which included $581 million and $863 million pre-tax goodwill impairment charges related to the Medical segment, respectively. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 of the "Notes to Condensed Consolidated Financial Statements" for additional detail related to goodwill impairment.
GAAP operating earnings during the three and six months ended December 31, 2022 were favorably impacted by litigation recoveries. See "Results of Operations" section of this MD&A and Note 6 of the "Notes to Condensed Consolidated Financial Statements" for additional detail related to litigation recoveries.
Non-GAAP operating earnings during the three and six months ended December 31, 2023 increased 20 percent and 27 percent, respectively, due to an increase in Pharmaceutical and Medical segment profit.
| 3 | Cardinal Health | Q2 Fiscal 2024 Form 10-Q |
| MD&A | Overview |
GAAP and Non-GAAP Diluted EPS
| Three Months Ended December 31, | Six Months Ended December 31, | ||||||||||||||||||||||||||||||||||
| ($ per share) | 2023 | 2022 | Change | 2023 | 2022 | Change | |||||||||||||||||||||||||||||
| GAAP diluted EPS (1) | $ | 1.43 | $ | (0.50) | N.M. | $ | 1.44 | $ | (0.08) | N.M. | |||||||||||||||||||||||||
| Surgical gown recall income | — | — | — | — | |||||||||||||||||||||||||||||||
| State opioid assessment related to prior fiscal years | — | (0.02) | — | (0.02) | |||||||||||||||||||||||||||||||
| Shareholder cooperation agreement costs | — | 0.01 | — | 0.02 | |||||||||||||||||||||||||||||||
| Restructuring and employee severance | 0.09 | 0.05 | 0.16 | 0.13 | |||||||||||||||||||||||||||||||
| Amortization and other acquisition-related costs | 0.19 | 0.20 | 0.38 | 0.40 | |||||||||||||||||||||||||||||||
| Impairments and (gain)/loss on disposal of assets, net (2) | 0.14 | 2.06 | ** |
Showing the first 8K of 80K characters. Open the full section
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in the quantitative and qualitative market risk disclosures included in our 2023 Form 10-K since the end of fiscal 2023 through December 31, 2023.
Item 4. Controls and Procedures
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of December 31, 2023. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of December 31, 2023, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 20 | Cardinal Health | Q2 Fiscal 2024 Form 10-Q |
| Other |
Legal Proceedings
The legal proceedings described in Note 6 of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.
Item 1A. Risk Factors
Risk Factors
You should carefully consider the information in this Form 10-Q, and the risk factors discussed in "Risk Factors" and other risks discussed in our 2023 Form 10-K, our Form 10-Q for the quarter ended September 30, 2023, and our other filings with the SEC since June 30, 2023. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.
Our pending acquisition of Specialty Networks subjects us to various risks and uncertainties.
As discussed in the MD&A section, on January 31, 2024, we announced that we had entered into a definitive agreement to acquire Specialty Networks for a purchase price of $1.2 billion in cash, subject to certain adjustments. The acquisition will further expand the Pharmaceutical segment's portfolio of Specialty services. We plan to fund the acquisition with available cash.
Consummation of the pending acquisition is subject to various risks and uncertainties, including the following: the ability to successfully complete the acquisition on a timely basis, including receipt of required regulatory approvals and satisfaction of other closing conditions; and the conditions of the credit markets.
If we are successful in completing the acquisition, we will be subject to other risks, including the following: we may fail to realize the synergies and other benefits we expect from the acquisition; the use of a significant portion of our cash may have an adverse effect on our liquidity, limit our flexibility in responding to other business opportunities, and increase our vulnerability to adverse economic and industry conditions; we may fail to retain key personnel of the acquired businesses; future developments may impair the value of our purchased goodwill or intangible assets; we may face difficulties establishing, integrating or combining operations and systems; we may face challenges retaining the customers of the acquired businesses; we may encounter unforeseen internal control, regulatory or compliance issues; and we may face other additional risks relating to regulatory matters, legal proceedings, and tax laws or positions.
Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities
Issuer Purchases of Equity Securities
| Period | Total Number of Shares Purchased (1) | Average Price Paid per Share (2,3) | Total Number of Shares Purchased as Part of Publicly Announced Programs (2,3,4) | Approximate Dollar Value of Shares That May Yet be Purchased Under the Program (4) (in millions) | |||||||||||||||||||
| October 2023 | 1,251,107 | $ | 79.94 | 1,250,909 | $ | 3,843 | |||||||||||||||||
| November 2023 | 1,967,452 | 101.66 | 1,967,342 | 3,543 | |||||||||||||||||||
| December 2023 | 444,271 | 112.57 | 444,161 | 3,493 | |||||||||||||||||||
| Total | 3,662,830 | $ | 95.57 | 3,662,412 | $ | 3,493 |
(1)Reflects 198, 110 and 110 common shares purchased in October, November and December 2023, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.
(2)On November 6, 2023, we entered into an ASR program to purchase common shares for an aggregate purchase price of $250 million and received an initial delivery of 2.0 million common shares using a reference price of $101.66. The ASR program concluded on December 13, 2023 at a volume weighted average price per common share of $103.67 resulting in a final delivery of 0.4 million common shares. See Note 10 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
(3)On August 16, 2023, we entered into an ASR program to purchase common shares for an aggregate purchase price of $500 million and received an initial delivery of 4.4 million common shares using a reference price of $90.57. The ASR program concluded on October 31, 2023 at a volume weighted average price per common share of $88.22 resulting in a final delivery of 1.3 million common shares. See Note 10 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
(4)On June 7, 2023, our Board of Directors approved a new $3.5 billion share repurchase program, which will expire on December 31, 2027. As of December 31, 2023, we had $3.5 billion authorized for share repurchases remaining under this program.
| 21 | Cardinal Health | Q2 Fiscal 2024 Form 10-Q |
Item 5. Other Information
| Other |
Other Information
Rule 10b5-1 Plan Adoptions and Modifications
During the three months ended December 31, 2023, no director or officer adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule10b5-1 trading arrangement" as each term is defined in Section 408(a) of Regulation S-K under the Exchange Act.
| 22 | Cardinal Health | Q2 Fiscal 2024 Form 10-Q |
| Financial Statements |
Item 1. Financial Statements
Condensed Consolidated Statements of Earnings/(Loss)
(Unaudited)
| Three Months Ended December 31, | Six Months Ended December 31, | ||||||||||||||||||||||
| (in millions, except per common share amounts) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Revenue | $ | 57,445 | $ | 51,469 | $ | 112,208 | $ | 101,072 | |||||||||||||||
| Cost of products sold | 55,599 | 49,806 | 108,594 | 97,795 | |||||||||||||||||||
| Gross margin | 1,846 | 1,663 | 3,614 | 3,277 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Distribution, selling, general and administrative expenses | 1,283 | 1,191 | 2,480 | 2,388 | |||||||||||||||||||
| Restructuring and employee severance | 28 | 17 | 53 | 46 | |||||||||||||||||||
| Amortization and other acquisition-related costs | 63 | 71 | 127 | 142 | |||||||||||||||||||
| Impairments and (gain)/loss on disposal of assets, net | 1 | 710 | 538 | 863 | |||||||||||||||||||
| Litigation (recoveries)/charges, net | (11) | (207) | (52) | (180) | |||||||||||||||||||
| Operating earnings/(loss) | 482 | (119) | 468 | 18 | |||||||||||||||||||
| Other (income)/expense, net | (16) | (7) | (18) | (5) | |||||||||||||||||||
| Interest expense, net | 8 | 25 | 22 | 50 | |||||||||||||||||||
| Earnings/(loss) before income taxes | 490 | (137) | 464 | (27) | |||||||||||||||||||
| Provision for/(benefit from) income taxes | 136 | (7) | 104 | (8) | |||||||||||||||||||
| Net earnings/(loss) | 354 | (130) | 360 | (19) | |||||||||||||||||||
| Less: Net earnings attributable to noncontrolling interests | (1) | — | (2) | (1) | |||||||||||||||||||
| Net earnings/(loss) attributable to Cardinal Health, Inc. | $ | 353 | $ | (130) | $ | 358 | $ | (20) | |||||||||||||||
| Earnings/(Loss) per common share attributable to Cardinal Health, Inc.: | |||||||||||||||||||||||
| Basic | $ | 1.44 | $ | (0.50) | $ | 1.45 | $ | (0.08) | |||||||||||||||
| Diluted | 1.43 | (0.50) | 1.44 | (0.08) | |||||||||||||||||||
| Weighted-average number of common shares outstanding: | |||||||||||||||||||||||
| Basic | 245 | 261 | 247 | 266 | |||||||||||||||||||
| Diluted | 246 | 261 | 248 | 266 | |||||||||||||||||||
| Cash dividends declared per common share | $ | 0.5006 | $ | 0.4957 | $ | 1.0012 | $ | 0.9914 |
See notes to condensed consolidated financial statements.
| 23 | Cardinal Health | Q2 Fiscal 2024 Form 10-Q |
| Financial Statements |
Condensed Consolidated Statements of Comprehensive Income/(Loss)
(Unaudited)
| Three Months Ended December 31, | Six Months Ended December 31, | ||||||||||||||||||||||
| (in millions) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Net earnings/(loss) | $ | 354 | $ | (130) | $ | 360 | $ | (19) | |||||||||||||||
| Other comprehensive income/(loss): | |||||||||||||||||||||||
| Foreign currency translation adjustments and other | 6 | 20 | (5) | (38) | |||||||||||||||||||
| Net unrealized gain on derivative instruments, net of tax | 4 | 10 | 1 | 6 | |||||||||||||||||||
| Total other comprehensive income/(loss), net of tax | 10 | 30 | (4) | (32) | |||||||||||||||||||
| Total comprehensive income/(loss) | 364 | (100) | 356 | (51) | |||||||||||||||||||
| Less: comprehensive income attributable to noncontrolling interests | (1) | — | (2) | (1) | |||||||||||||||||||
| Total comprehensive income/(loss) attributable to Cardinal Health, Inc. | $ | 363 | $ | (100) | $ | 354 | $ | (52) |
See notes to condensed consolidated financial statements.
| 24 | Cardinal Health | Q2 Fiscal 2024 Form 10-Q |
| Financial Statements |
Condensed Consolidated Balance Sheets
| (in millions) | December 31, 2023 | June 30, 2023 | |||||||||
| (Unaudited) | |||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and equivalents | $ | 4,591 | $ | 4,043 | |||||||
| Trade receivables, net | 11,788 | 11,344 |
Showing the first 8K of 106K characters. Open the full section
Item 6. Exhibits
| Exhibits |
Exhibits
Cardinal Health Website
Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases, SEC filings and certain other information on its website.
| 42 | Cardinal Health | Q2 Fiscal 2024 Form 10-Q |
| Form 10-Q Cross Reference Index |
Form 10-Q Cross Reference Index
| Item Number | Page | |||||||
| Part I. Financial Information | ||||||||
| Item 1 | Financial Statements | 23 | ||||||
| Item 2 | Management's Discussion and Analysis of Financial Condition and Results of Operations | 2 | ||||||
| Item 3 | Quantitative and Qualitative Disclosures about Market Risk | 20 | ||||||
| Item 4 | Controls and Procedures | 20 | ||||||
| Part II. Other Information | ||||||||
| Item 1 | Legal Proceedings | 21 | ||||||
| Item 1A | Risk Factors | 21 | ||||||
| Item 2 | Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities | 21 | ||||||
| Item 3 | Defaults Upon Senior Securities | N/A | ||||||
| Item 4 | Mine Safety Disclosures | N/A | ||||||
| Item 5 | Other Information | 22 | ||||||
| Item 6 | Exhibits | 42 | ||||||
| Signatures | 44 |
| N/A | Not applicable |
| 43 | Cardinal Health | Q2 Fiscal 2024 Form 10-Q |
| Additional Information |
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Cardinal Health, Inc. | ||||||||
| Date: | February 1, 2024 | /s/ JASON M. HOLLAR | ||||||
| Jason M. Hollar | ||||||||
| Chief Executive Officer | ||||||||
| /s/ AARON E. ALT | ||||||||
| Aaron E. Alt | ||||||||
| Chief Financial Officer |
| 44 | Cardinal Health | Q2 Fiscal 2024 Form 10-Q |